News | September 02, 2014

Elekta’s Enhanced Collaboration With Toshiba Strengthens Position in Japan

September 2, 2014 — In an agreement signed in Tokyo, Elekta Japan will grant Toshiba Medical Systems Corp. (TMSC) wider distribution rights regarding linear accelerator (linac) sales. The agreement builds on a sales and marketing agreement from 2010.

Shuichi Higaki, president and managing director, Elekta Japan, said: “The existing partnership between Elekta and TMSC from 2010 has helped raise Elekta’s profile in the Japanese market. This new agreement creates significant opportunities for Elekta to further increase our customer satisfaction and become the leading supplier of oncology systems and related software solutions in Japan.”

Since Siemens’s departure from the linac market in 2011, TMSC still has an installed base of about 200 aging Siemens linear accelerators. The extended partnership opens up additional sales channels for Elekta’s linacs and software products and gives Elekta the opportunity to convert existing Siemens Lantis oncology information systems (OIS) that were sold through TMSC.

The agreement also includes the intention to develop the Elekta Support Center, a centralized customer support center with a single point of contact for all Elekta linac users in Japan. Elekta will continue to manage marketing and promotion of all Elekta products and solutions, as well as education and training and software service support.

For more information: www.elekta.com

Related Content

With a wealth of landmark studies in Breast, Cervical, Melanoma, Prostate, Colorectal, Oesophagus, Endocrine and Lung cancer, the ESMO Congress 2021 is a clear demonstration that oncology research has once again gathered momentum after being temporarily stopped in its tracks by the outbreak of the virus

Getty Images

News | Radiation Oncology | September 13, 2021
September 13, 2021 — At the opening press conference of the ...
Comment letters on the 2022 physician fee schedule and Radiation Oncology Model urge CMS to scale back extreme cuts that jeopardize access to life-saving cancer treatments

Getty Images

News | ASTRO | September 09, 2021
September 9, 2021 — The American Society for Radiation Oncology (AS...
Cedars-Sinai Cancer researchers have discovered that intestinal microorganisms help regulate anti-tumor immune responses to radiation treatments.

Getty Images

News | Radiation Therapy | September 01, 2021
September 1, 2021 — The study, published on Aug.
RefleXion Medical, Inc., a therapeutic oncology company pioneering biology-guided radiotherapy (BgRT) as a new modality that will one day treat all stages of cancer,announced the sale of its RefleXion X1 machine to The Center for Cancer and Blood Disorders, a free-standing cancer treatment center with 15 locations throughout northern Texas.

RefleXion Medical announces the sale of its X1 machine to The Center for Cancer and Blood Disorders in Texas. (Photo: Business Wire)

News | Radiation Therapy | August 23, 2021
August 23, 2021 — ...
The global radiotherapy market is forecasted to reach USD 7987.01 Million in the year 2020, according to the "Global Radiotherapy Market - Analysis By Procedure (External Radiation, Internal Radiation), Product, Application, By Region, By Country (2021 Edition): Market Insights and Forecast with Impact of COVID-19 (2021-2026)" report from ResearchAndMarkets.com
News | Radiation Therapy | August 20, 2021
August 20, 2021 — The global radiotherapy market is forecasted to reach $8.29 billion in the year 2021, according to